Registrant : Organisation or self-employed individual
| Name/company name: |
GlaxoSmithKline |
| Acronym: |
GSK
|
| Legal status: |
Corporation
|
| Website address: |
http://www.gsk.com
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
Andrew Witty
|
| Position: |
Chief Executive Officer |
Permanent person in charge of EU relations
| Surname, Name: |
Mr
Johan Thor
|
| Position: |
Vice President European Government Affairs |
Contact details:
| Contact details of organisation's head office: |
980 Great West Road
Brentford, Middlesex TW8 9GS
UNITED KINGDOM
|
| Telephone number: |
(+44) 20 8047 5000 |
| Fax number: |
(+) |
| Other contact information: |
Contact details of Brussels office:
GlaxoSmithKline
Kunstlaan 46 Avenue Des Arts
1000 Brussels
Belgium
Tel: +32 (0) 2 282 40 55
|
Goals / remit
| Goals / remit of the organisation: |
GlaxoSmithKline (GSK) is a research-based pharmaceutical company. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.
Headquartered in the UK, we are one of the industry leaders with an estimated seven per cent of the world's pharmaceutical market. We produce medicines that treat major disease areas, including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions, and we market over 25 vaccines to protect against illnesses such as hepatitis A and B, diphtheria, tetanus,whooping cough, typhoid and influenza. GSK also produce consumer health care products including, over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks.
We believe we are the only pharmaceutical company researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. In 2007, our total community investment was valued at £282 million, equivalent to 3.8 per cent of Group total profit before tax.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
3.2
|
|
Complementary information:
|
The number of persons reflect the full time employement falling under the scope of the register.
|
Persons accredited for access to European Parliament premises
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
- to adress unmet medical needs, improve patient safety and strengthen disease prevention in Europe
- to increase Europe´s competitiveness as a location for Research and Development investment
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Competition
- Consumer Affairs
- Employment and Social Affairs
- Enterprise
- Humanitarian Aid
- Internal Market
- Public Health
- Research and Technology
- Trade
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
EFPIA - European Federation of Pharmaceutical Industries and Associations
EUROPABIO
AESGP
|
Financial data
| Financial year: |
01/2012
-
12/2012
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
900000
€ - 1000000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
In 2012, costs associated with lobbying of EU institutions were in the range of 900.000-950.000. This figure is calculated based on the Interinstitutional Agreements published in the Official Journal of 22 July 2011 and includes:
•A percentage of the salaries of the staffers falling under the scope of the Register
•The full time employment cost of 1 accredited staffer in 2012.
•A percentage of the overall costs of running an office in Brussels
•100% of GSK spend on conferences dedicated to “EU Public Affairs”
•A percentage of the costs incurred by the staffers falling under the scope of the Register for travel and accommodation related to EU Public Affairs activities
•100% of the consulting cost spent on EU Public Affairs advice.
In order to avoid double reporting on the Register, this figure excludes trade association membership fees as responsibility for declaring these lies with the respective organisations. The 2012 figure is greater than GSK’s 2011 figure because we added the full costs of the accredited staffer and because office costs increased.
|
|
